Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MLN9708 for Chronic GVHD Prophylaxis
NCT02250300Phase 2Completed
- Start
- Nov 2014
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ixazomib in chronic graft-versus-host disease (cGVHD) (5 arms). Primary endpoints: Maximum-tolerated Dose of MLN9708 at 4 weeks, Cumulative Incidence of Chronic Graft-versus-host Disease at 1 year and 1 more. Started Nov 2014; status: completed.
02
Drugs
ixazomib
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT02250300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02250300.